Novo's CagriSema leads to 25% weight loss in women
· seekingalpha.com
Novo Nordisk’s CagriSema phase 3 data shows ~25% weight loss at 68 weeks across menopausal groups. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...